HANGZHOU, China | December 24, 2025 — WORK Medical Technology Group LTD, a China-based supplier of Class I and Class II medical devices, announced the implementation of a 1-for-100 reverse stock split, effective December 29, 2025. The action, approved by both shareholders and the board of directors, is designed to maintain compliance with Nasdaq minimum bid price requirements, while preserving shareholder ownership proportions and supporting the company’s long-term position as a regulated global MedTech manufacturer.
Science Significance
Although primarily a corporate action, the reverse stock split has indirect scientific relevance by supporting the sustainability of regulated medical device innovation. WORK Medical develops and manufactures a diverse portfolio of medical consumables and treatment equipment, including masks and other disposable devices used in clinical and healthcare settings. Continued Nasdaq compliance enables the company to access capital markets essential for funding product development, design validation, and manufacturing scale-up, all of which underpin evidence-based device performance and lifecycle management in the MedTech sector.
Regulatory Significance
From a regulatory standpoint, the announcement underscores the intersection between capital market compliance and medical device regulation. The reverse split was undertaken specifically to meet Nasdaq Marketplace Rule 5550(a)(2), reflecting disciplined corporate governance in a regulated environment. WORK Medical already operates under stringent quality and regulatory frameworks, including multiple FDA product registrations that allow its devices to enter the U.S. market. Maintaining listing compliance supports ongoing FDA registration maintenance, quality system adherence, and post-market obligations, all of which are critical for companies operating under medical device regulatory regimes.
Business Significance
Advertisement
Strategically, the reverse stock split is a defensive yet stabilizing business measure that strengthens WORK Medical’s standing in global capital markets. By consolidating shares while rounding up fractional holdings, the company avoids dilution and preserves shareholder value. Continued Nasdaq listing enhances investor confidence, liquidity, and visibility, enabling the company to pursue international expansion, portfolio diversification, and operational investments. For a MedTech manufacturer with products sold across 34 provincial regions in China and more than 30 international markets, financial stability is directly linked to execution across regulated supply chains.
Patients’ Significance
For patients and healthcare providers, the implications are indirect but meaningful. WORK Medical supplies widely used disposable medical devices that support infection control, clinical procedures, and frontline healthcare delivery. Ensuring financial and operational continuity helps guarantee consistent product availability, manufacturing quality, and supply reliability, particularly for consumables that are critical to routine patient care. Corporate actions that stabilize the company ultimately contribute to uninterrupted access to compliant medical devices across healthcare systems.
Policy Significance
At a policy level, the announcement reflects how financial governance and healthcare regulation increasingly converge. Policymakers and regulators rely on transparent, well-governed companies to ensure that medical device manufacturers can meet safety, quality, and reporting obligations. WORK Medical’s proactive step to remain Nasdaq-compliant demonstrates alignment with broader policy objectives around market transparency, investor protection, and the integrity of regulated healthcare suppliers operating across borders.
Overall, WORK Medical Technology Group’s reverse stock split represents more than a financial adjustment—it is a strategic governance action that supports the company’s role within the regulated MedTech ecosystem. By safeguarding Nasdaq compliance, the company reinforces its capacity to sustain quality-driven manufacturing, regulatory adherence, and global device supply. For the cGxP and MedTech community, the move highlights how corporate discipline and regulatory readiness remain foundational to long-term medical device innovation and patient trust.
Source: WORK Medical Technology Group LTD press release
